| Drug General Information |
| Drug ID |
D0TD2G
|
| Former ID |
DCL000735
|
| Drug Name |
Canakinumab
|
| Synonyms |
Ilaris (TN)
|
| Drug Type |
Antibody
|
| Indication |
Cryopyrin-associated periodic syndromes; Rheumatoid arthritis [ICD9: 277.31, 322.2, 339.8, 708.2, 708.8, 714.3, 710-719, 714; ICD10:E85.0, G03.1, G44.8, L50.2, L50.8, M08.9, M05-M06]
|
Approved |
[1],
[2]
|
|---|
|
Urticaria; Vasculitis [ICD9: 446, 447.6, 708; ICD10:I77.6, I80, L50, L95, M30-M31]
|
Phase 2 |
[1],
[2]
|
| Company |
Novartis
|
| CAS Number |
CAS 914613-48-2
|
| SuperDrug ATC ID |
L04AC08
|
| Target and Pathway |
| Target(s) |
Interleukin-1 beta |
Target Info |
|
[1],
[3]
|
|---|
|
KEGG Pathway
|
MAPK signaling pathway
|
|
Cytokine-cytokine receptor interaction
|
|
NF-kappa B signaling pathway
|
|
Apoptosis
|
|
Osteoclast differentiation
|
|
Toll-like receptor signaling pathway
|
|
NOD-like receptor signaling pathway
|
|
Cytosolic DNA-sensing pathway
|
|
Hematopoietic cell lineage
|
|
TNF signaling pathway
|
|
Inflammatory mediator regulation of TRP channels
|
|
Non-alcoholic fatty liver disease (NAFLD)
|
|
Type I diabetes mellitus
|
|
Alzheimer's disease
|
|
Prion diseases
|
|
Salmonella infection
|
|
Pertussis
|
|
Legionellosis
|
|
Leishmaniasis
|
|
Chagas disease (American trypanosomiasis)
|
|
African trypanosomiasis
|
|
Malaria
|
|
Amoebiasis
|
|
Tuberculosis
|
|
Measles
|
|
Influenza A
|
|
Herpes simplex infection
|
|
Inflammatory bowel disease (IBD)
|
|
Rheumatoid arthritis
|
|
Graft-versus-host disease
|
|
NetPath Pathway
|
Leptin Signaling Pathway
|
|
IL5 Signaling Pathway
|
|
IL1 Signaling Pathway
|
|
IL2 Signaling Pathway
|
|
IL3 Signaling Pathway
|
|
TGF_beta_Receptor Signaling Pathway
|
|
Wnt Signaling Pathway
|
|
TCR Signaling Pathway
|
|
TNFalpha Signaling Pathway
|
|
Pathway Interaction Database
|
IL27-mediated signaling events
|
|
IL12-mediated signaling events
|
|
IL1-mediated signaling events
|
|
IFN-gamma pathway
|
|
IL23-mediated signaling events
|
|
Cellular roles of Anthrax toxin
|
|
Reactome
|
Interleukin-1 signaling
|
|
Interleukin-1 processing
|
|
CLEC7A/inflammasome pathway
|
|
WikiPathways
|
Toll-like receptor signaling pathway
|
|
Monoamine Transport
|
|
SIDS Susceptibility Pathways
|
|
TCR Signaling Pathway
|
|
Type II interferon signaling (IFNG)
|
|
Senescence and Autophagy in Cancer
|
|
Cytokines and Inflammatory Response
|
|
MAPK Signaling Pathway
|
|
Myometrial Relaxation and Contraction Pathways
|
|
Aryl Hydrocarbon Receptor Pathway
|
|
IL1 and megakaryotyces in obesity
|
|
Hematopoietic Stem Cell Differentiation
|
|
Spinal Cord Injury
|
|
Allograft Rejection
|
|
Alzheimers Disease
|
|
Leptin signaling pathway
|
|
IL-1 signaling pathway
|
|
Interleukin-1 signaling
|
|
Folate Metabolism
|
|
Vitamin B12 Metabolism
|
|
Selenium Micronutrient Network
|
|
Serotonin Transporter Activity
|
|
Regulation of toll-like receptor signaling pathway
|
|
NOD pathway
|
| References |
| REF 1 | Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. |
|---|
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6773). |
|---|
| REF 3 | Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96. |
|---|
